Abstract：
In this study, we aimed to evaluate the efficacy of PD-1 inhibitors in combination with concurrent CRT/CT for patients with inoperable ESCC in the real world and to find predictors for the efficacy of PD-1 inhibitors. Patients with unresectable ESCC were evaluated at baseline. The clinical data of patients with ESCC who received CRT/CT with or without PD-1 inhibitor were collected and retrospectively reviewed. The objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) were analyzed statistically. A total of 96 patients with ESCC were included. As compared with a control group (n = 48), the PFS (6.0 months vs. 5.0 months, p = 0.025) and 6-month OS (70.8% vs. 47.9%, p < 0.001) were significantly longer in the ICIs group (n = 48). There were no significant differences in ORR and 12-month OS between the two groups. In addition, we found that body mass index (BMI) was associated with PFS (HR 0.85, 95% CI 0.76−0.95, and p = 0.004) and OS (HR 0.82, 95% CI 0.69−0.98, and p = 0.033) in the ICIs group. PD-1 inhibitors combined with CRT/CT is safe with acceptable complications and improved survival for patients with inoperable ESCC. CRT plus PD-1 inhibitor has superior antitumor efficacy. BMI was positively correlated with the efficacy of PD-1 inhibitors.
摘要：
在这项研究中,我们的目的是评估PD-1抑制剂联合同步CRT/CT对现实世界中无法手术的ESCC患者的疗效,并寻找PD-1抑制剂疗效的预测因子.在基线时评估不可切除的ESCC患者。回顾性分析接受CRT/CT联合或不联合PD-1抑制剂治疗的ESCC患者的临床资料。客观反应率(ORR)，总生存期（OS），对无进展生存期(PFS)进行统计学分析。共纳入96例ESCC患者。与对照组(n=48)相比，PFS(6.0个月与5.0个月,p=0.025）和6个月OS（70.8%与47.9%,p<0.001）在ICIs组（n=48）中明显更长。两组之间的ORR和12个月OS没有显着差异。此外,我们发现,在ICIs组中,体重指数(BMI)与PFS(HR0.85,95%CI0.76-0.95,p=0.004)和OS(HR0.82,95%CI0.69-0.98,p=0.033)相关.PD-1抑制剂联合CRT/CT是安全的，并发症可接受，并且无法手术的ESCC患者的生存率提高。CRT加PD-1抑制剂具有优越的抗肿瘤疗效。BMI与PD-1抑制剂的疗效呈正相关。
